Optimizing Multidisciplinary Approaches in the Guideline-Driven Management of Cervical and Endometrial Cancers 16.12.2025 44:30

Faculty: Brian Slomovitz, MD This activity focuses on optimizing multidisciplinary strategies in the guideline-driven management of cervical and endometrial cancers. Dr. Brian Slomovitz presents recent and emerging clinical data for immunotherapy-based treatment strategies, explores the role of screening and biomarkers, and emphasizes interprofessional collaboration across oncology specialties. Ca...

Optimizing Multidisciplinary Approaches in the Guideline-Driven Management of Cervical and Endometrial Cancers 16.12.2025 44:30

Faculty: Brian Slomovitz, MD This activity focuses on optimizing multidisciplinary strategies in the guideline-driven management of cervical and endometrial cancers. Dr. Brian Slomovitz presents recent and emerging clinical data for immunotherapy-based treatment strategies, explores the role of screening and biomarkers, and emphasizes interprofessional collaboration across oncology specialties. Ca...

Are You On Top of Pediatric Atopic Dermatitis? Expert Guidance for Leveraging the Latest Advances in Systemic Therapy 15.12.2025 54:30

Host: Peter A. Lio, MD Guest: Wendy Smith Begolka Guest: Elizabeth Swanson, MD, FAAD On-demand webcast of expert faculty presentation on the disease burden of pediatric atopic dermatitis and strategies for helping patients achieve disease control with systemic therapy.

All Sides of the Joint: Integrated TGCT Care Across Specialties 15.12.2025 5:30

Faculty: A.J. Gelderblom, MD, PhD Faculty: Michiel van de Sande, MD, PhD Faculty: Chelsea Cole, MD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The...

Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy 15.12.2025 5:15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT 15.12.2025 5:15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians 15.12.2025 4:45

Faculty: A.J. Gelderblom, MD, PhD Faculty: Chelsea Cole, MD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical...

Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs 15.12.2025 5:45

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT 15.12.2025 5:00

Faculty: A.J. Gelderblom, MD, PhD Faculty: Michiel van de Sande, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence...

Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R 15.12.2025 4:45

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices 15.12.2025 4:45

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

Beyond the Scalpel: When TGCT Surgery Isn’t the Solution 15.12.2025 5:00

Faculty: Michiel van de Sande, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhi...

The Tumor That’s Not So Tiny: Understanding the Impact of TGCT 15.12.2025 5:00

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis 15.12.2025 24:15

Host: Pushpa Narayanaswami, MD, FAAN In this expert commentary, Dr. Narayanaswami highlights key messages from the Prova Education satellite symposium held at the 2025 AANEM Meeting in San Francisco. The discussion centers on the clinical application of FcRn antagonists in gMG, reviewing the rationale for FcRn blockade, approved FcRN antagonists, and pivotal clinical trial data. Differences in the...